Micronase Related Published Studies
Well-designed clinical trials related to Micronase (Glyburide)
Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. [2009.07]
Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. [2009.05]
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. [2008.07]
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. [2007.11]
Glyburide for the treatment of gestational diabetes. A critical appraisal. [2007.07]
Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. [2007.05]
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. [2007.02]
Bioequivalence of two oral formulations of glyburide (glibenclamide). [2007]
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [2006.12.07]
Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. [2006.01]
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. [2005.09]
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [2005.09]
Well-designed clinical trials possibly related to Micronase (Glyburide)
Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. [2009.05]
Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. [2009.03]
Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. [2009.02]
Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. [2009.01]
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. [2009]
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. [2008.10]
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. [2008.06]
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. [2008.05]
Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. [2008.05]
Treating the mother - protecting the unborn: The safety of hypoglycemic drugs in pregnancy. [2008.03]
Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. [2007.11]
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. [2007.11]
Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. [2007.09]
Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. [2007.09]
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. [2007.08]
Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS. [2007.07.01]
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. [2007.06]
[Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin] [2007.06]
Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]
Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. [2007.04]
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. [2007.01]
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?] [2007.01]
Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. [2007]
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. [2006.12]
Insulins and oral hypoglycemic agents in pregnancy. [2006.11]
Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. [2006.10]
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. [2006.10]
Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. [2006.09]
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. [2006.09]
Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. [2006.09]
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. [2006.08]
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. [2006.08]
Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.07]
Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. [2006.06]
Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study. [2006.05]
Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. [2006.04]
Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication. [2006.03]
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. [2006.03]
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. [2006.02]
Improving metabolic control leads to better working memory in adults with type 2 diabetes. [2006.02]
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. [2006.02]
Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. [2006.02]
The efficacy of folk medicines in the management of type 2 diabetes mellitus: results of a randomized controlled trial of Syzygium cumini (L.) Skeels. [2006.02]
Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. [2006.01]
Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. [2006]
Effects of pharmacological modulation of the ATP-sensitive potassium channels on the development of warm-up angina pectoris. [2006]
Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. [2005.12.06]
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]
The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). [2005.11]
Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. [2005.09]
Effect of ischaemic preconditioning on regional release of inflammatory markers. [2005.09]
Efficacy of glimepiride in Japanese type 2 diabetic subjects. [2005.06]
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. [2005.05]
Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. [2005.04]
Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. [2005.02.15]
Repaglinide administration improves brachial reactivity in type 2 diabetic patients. [2005.02]
Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. [2005.01]
Perinatal outcomes and the use of oral hypoglycemic agents. [2005]
Other research related to Micronase (Glyburide)
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. [2009.10]
Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. [2009.09.29]
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. [2009.06]
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. [2009.04]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. [2009.02]
Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. [2009.01]
Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies. [2009]
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone. [2008.12]
Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up. [2008.09]
Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. [2008.08]
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. [2008.07]
Investigating the potential role of multi-drug resistance protein (MRP) transporters in fetal to maternal glyburide efflux in the human placenta. [2008.07]
Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide. [2008.06]
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. [2008.05.22]
Glyburide for the treatment of gestational diabetes mellitus. [2008.05]
Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. [2008.04]
Safety of Glyburide for Gestational Diabetes: A Meta-Analysis of Pregnancy Outcomes (April). [2008.03.18]
The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. [2008.03]
Glyburide metabolism by placentas of healthy and gestational diabetics. [2008.03]
Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide. [2008.03]
Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. [2007.11]
Beneficial Effects of Glucagon-like peptide-1 (GLP-1) on Endothelial Function in Humans: Dampening by Glyburide but not by Glimepiride. [2007.08.21]
Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11. [2007.08]
Adult glyburide ingestions reported to Texas poison control centers, 1998 2005. [2007.07]
Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. [2007.05]
The effect of the sulfonylurea glyburide on glutathione-S-transferase and glucose-6-phosphate dehydrogenase in streptozotocin-induced diabetic rat liver. [2006.12]
Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. [2006.10]
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. [2006.10]
Biorelevant dissolution media as a predictive tool for glyburide a class II drug. [2006.09]
|
